McKesson Corporation faced a significant decline in their stock as the company failed to meet quarterly revenue estimates. A shortfall in the supply and demand for weight-loss drugs hampered their revenue. However, their earnings per share soared, and the company managed to beat Q1 earnings estimates. The results revealed an overall increase in year-on-year revenues. The company's U.S. pharmaceutical segment posed a significant challenge. Despite the revenue miss, investment advisory firm Mizuho raised its target for Mckesson's stock. An interesting aspect of Mckesson's ownership structure showed that institutional shareholders control 88% of the company. The company posted strong revenue growth for Q1 2025, raising their full-year guidance even amidst an earnings dip. The stock price has seen enviable returns over the past five years and has gained 26% year-to-date, which indicated strong market momentum. However, the company faced a downgrade from certain analysts. The company has high institutional ownership of 88%, and its stock has outperformed competitors on multiple trading days. Mckesson has also increased its quarterly dividend by 15%.
Mckesson Corporation MCK News Analytics from Fri, 19 Jan 2024 08:00:00 GMT to Sun, 11 Aug 2024 14:03:39 GMT -
Rating 0
- Innovation -2
- Information 5
- Rumor -4
